pentobarbital will reduce the extent or outcome of alosetron by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Unfamiliar.
pentobarbital will reduce the extent or outcome of etravirine by impacting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Keep an eye on.
pentobarbital will minimize the extent or outcome of fostemsavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
pentobarbital will decrease the extent or impact of mestranol by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.
pentobarbital will minimize the level or impact of buprenorphine buccal by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
Comment: Barbiturates may improve adverse outcomes, together with respiratory melancholy, made by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates enhance metabolism and reduce blood concentrations of TCAs.
pentobarbital will lessen the extent or impact of zaleplon by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Unidentified.
pentobarbital will decrease the extent or outcome of amiodarone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
pentobarbital will reduce the level or influence of pantoprazole by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Significance Mysterious.
pentobarbital will reduce the extent or impact of atazanavir by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Importance Mysterious.
pentobarbital will lessen the level or outcome of diazepam buccal by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check. Solid or reasonable CYP3A4 inducers could increase level of diazepam elimination; hence, efficacy of diazepam might be diminished.
pentobarbital will lessen the level or result of ambrisentan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Unidentified.
pentobarbital will lower the website level or effect of alfentanil by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Significance Not known.
Likely for Bogus optimistic check success if macimorelin and powerful CYP3A4 inducers are coadministered. Discontinue sturdy CYP3A4 inducer, making it possible for for adequate washout time, prior to tests.